Michael Sinha

@drsinhaesq.bsky.social

MD JD MPH FCLM FAMWA • Associate Prof @SLUHealthLaw.bsky.social @SLULAW.bsky.social • Former #NUSLHealth @PORTALResearch.org #HarvardMIT_CRS #HeForShe • 🇮🇸 🇮🇳 🇺🇸

Glad to join @sbagen.bsky.social and @drsinhaesq.bsky.social on this panel at @nusl.bsky.social's annual health law conference, with very thoughtful moderation from @davidasimon.bsky.social. Thanks to @doritreiss.bsky.social for liveposting!

Dorit Reiss@doritreiss.bsky.social · 4mo ago

Says @rachelsachs.bsky.social in the panel on the FDA regulatory environment in #HLC2026 in @NUSL: because drug development path is long, important that companies can trust that advice they get at point A will hold. High turnout - companies reporting - advice from FDA changing, moving goal posts.